Journal: NPJ precision oncology
This study evaluated OncoSeek, an AI-powered blood-based multi-cancer early detection (MCED) test, across 15,122 participants—including 3,029 cancer patients—using data from seven centers in three countries, four platforms, and two sample types.
OncoSeek demonstrated strong performance with:
- AUC: 0.829
- Sensitivity: 58.4%
- Specificity: 92.0%
- Accuracy in predicting tissue of origin for true positives: 70.6%
The test detected 14 common cancer types responsible for 72% of global cancer deaths, with sensitivities ranging from 38.9% to 83.3%.
In symptomatic patients, sensitivity increased to 73.1% at 90.6% specificity, highlighting its potential for early diagnosis.
Consistent results across diverse populations and settings suggest OncoSeek is a promising, affordable, and accessible MCED tool, especially valuable for low- and middle-income countries.